See more : Canaccord Genuity Group Inc. (CF.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Global Cord Blood Corporation (CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Cord Blood Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Enjin Co., Ltd. (7370.T) Income Statement Analysis – Financial Results
- Mondi plc (MONDF) Income Statement Analysis – Financial Results
- Environmental Service Professionals, Inc. (EVSP) Income Statement Analysis – Financial Results
- Strategic Minerals Europe Corp. (SNTAF) Income Statement Analysis – Financial Results
- Tidewater Inc. Series A (TDW-WTA) Income Statement Analysis – Financial Results
Global Cord Blood Corporation (CO)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.globalcordbloodcorp.com
About Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.24B | 1.16B | 1.22B | 986.75M | 936.77M | 759.98M | 663.00M | 635.12M | 572.86M | 526.12M | 380.49M | 339.53M | 261.54M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 183.31M | 178.95M | 189.13M | 186.03M | 181.48M | 142.64M | 144.60M | 130.61M | 106.23M | 106.62M | 86.66M | 77.38M | 65.73M | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.06B | 980.69M | 1.03B | 800.73M | 755.29M | 617.34M | 518.40M | 504.51M | 466.63M | 419.50M | 293.83M | 262.16M | 195.81M | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 85.26% | 84.57% | 84.52% | 81.15% | 80.63% | 81.23% | 78.19% | 79.44% | 81.46% | 79.73% | 77.22% | 77.21% | 74.87% | 0.00% | 0.00% | 0.00% |
Research & Development | 22.30M | 23.77M | 21.11M | 14.69M | 12.72M | 10.37M | 8.96M | 9.91M | 9.77M | 8.46M | 7.62M | 6.96M | 5.82M | 0.00 | 0.00 | 0.00 |
General & Administrative | 187.06M | 174.36M | 190.23M | 169.32M | 243.50M | 189.94M | 169.95M | 131.68M | 112.24M | 108.05M | 89.70M | 83.79M | 53.32M | 11.20M | 0.00 | 0.00 |
Selling & Marketing | 241.73M | 237.69M | 261.96M | 235.06M | 219.20M | 178.48M | 148.16M | 127.93M | 112.69M | 93.68M | 61.68M | 47.58M | 39.48M | 0.00 | 0.00 | 0.00 |
SG&A | 428.79M | 412.05M | 452.19M | 404.38M | 462.70M | 368.42M | 318.11M | 259.61M | 224.93M | 201.73M | 151.37M | 131.38M | 92.80M | 11.20M | 4.01M | 66.28K |
Other Expenses | 6.27M | 8.16M | 7.39M | 5.70M | 4.23M | 5.97M | -113.00K | 861.00K | 2.21M | 203.00K | 0.00 | 0.00 | 0.00 | 594.98K | 220.52K | 166.41K |
Operating Expenses | 451.08M | 435.82M | 473.30M | 419.07M | 475.42M | 352.47M | 327.07M | 269.52M | 234.71M | 210.19M | 158.99M | 138.34M | 98.61M | 11.80M | 4.23M | 232.69K |
Cost & Expenses | 634.39M | 614.77M | 662.43M | 605.10M | 656.91M | 495.11M | 471.67M | 400.13M | 340.93M | 316.81M | 245.65M | 215.71M | 164.34M | 11.80M | 4.23M | 232.69K |
Interest Income | 32.61M | 30.90M | 25.36M | 25.32M | 21.94M | 17.42M | 18.22M | 18.25M | 16.87M | 15.06M | 13.43M | 9.07M | 6.41M | 4.11M | 0.00 | 250.79K |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 3.26M | 119.42M | 107.97M | 101.10M | 70.08M | 70.10M | 3.29M | 2.61M | 2.43M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 19.91M | -26.82M | 12.97M | 52.37M | 50.59M | 50.48M | 50.17M | 50.61M | 37.07M | 35.87M | 29.36M | 23.48M | 20.43M | 3.92M | 7.10M | 250.79K |
EBITDA | 628.78M | 518.05M | 572.00M | 404.75M | 353.60M | 333.71M | 299.10M | 306.33M | 297.44M | 256.96M | 174.26M | 151.71M | 96.81M | -7.88M | 2.87M | 18.11K |
EBITDA Ratio | 50.58% | 44.67% | 46.83% | 41.02% | 37.75% | 43.91% | 45.11% | 48.23% | 51.92% | 48.84% | 45.80% | 44.68% | 37.02% | 0.00% | 0.00% | 0.00% |
Operating Income | 608.87M | 544.87M | 559.03M | 381.66M | 279.86M | 264.87M | 191.33M | 235.00M | 231.93M | 209.31M | 134.84M | 123.82M | 97.19M | -11.80M | -4.23M | -232.69K |
Operating Income Ratio | 48.97% | 46.99% | 45.77% | 38.68% | 29.88% | 34.85% | 28.86% | 37.00% | 40.49% | 39.78% | 35.44% | 36.47% | 37.16% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 18.97M | 65.88M | 19.78M | -25.20M | 23.67M | -98.55M | -50.00M | -79.88M | -41.00M | -51.13M | 16.76M | 8.32M | -17.53M | 3.92M | 7.10M | 250.79K |
Income Before Tax | 627.84M | 610.75M | 578.81M | 356.46M | 303.54M | 166.31M | 141.33M | 155.12M | 190.92M | 158.19M | 151.60M | 132.14M | 79.66M | -7.88M | 2.87M | 18.11K |
Income Before Tax Ratio | 50.50% | 52.67% | 47.39% | 36.12% | 32.40% | 21.88% | 21.32% | 24.42% | 33.33% | 30.07% | 39.84% | 38.92% | 30.46% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 118.35M | 94.55M | 101.08M | 61.26M | 62.66M | 37.62M | 50.00M | 47.33M | 58.40M | 38.54M | 9.63M | 33.93M | 24.77M | -4.11M | -7.47M | -18.11K |
Net Income | 501.07M | 508.25M | 470.72M | 291.12M | 237.10M | 126.19M | 90.97M | 107.29M | 131.90M | 112.45M | 131.98M | 91.70M | 49.18M | -7.88M | 2.87M | 18.11K |
Net Income Ratio | 40.30% | 43.83% | 38.54% | 29.50% | 25.31% | 16.60% | 13.72% | 16.89% | 23.03% | 21.37% | 34.69% | 27.01% | 18.80% | 0.00% | 0.00% | 0.00% |
EPS | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.69 | -1.13 | 0.41 | 0.01 |
EPS Diluted | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.66 | -1.13 | 0.41 | 0.01 |
Weighted Avg Shares Out | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 71.27M | 7.00M | 7.00M | 1.49M |
Weighted Avg Shares Out (Dil) | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 74.51M | 7.00M | 7.00M | 1.49M |
CO, CORBF DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
CO, CORBF Deadline: CO, CORBF Investors Have the Opportunity to Lead Global Cord Blood Corporation Securities Fraud Lawsuit
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Global Cord Blood Corporation (CORBF)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBF
ROSEN, A LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
Rosen Law Firm Urges Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
Source: https://incomestatements.info
Category: Stock Reports